Copyright Reports & Markets. All rights reserved.

Global Long Acting Beta 2 Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Long Acting Beta 2 Agonist
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Long Acting Beta 2 Agonist Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Serevent
    • 1.3.3 Foradil
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Long Acting Beta 2 Agonist Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 COPD
    • 1.4.3 Asthma
    • 1.4.4 Other
  • 1.5 Global Long Acting Beta 2 Agonist Market Size & Forecast
    • 1.5.1 Global Long Acting Beta 2 Agonist Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Long Acting Beta 2 Agonist Sales Quantity (2018-2029)
    • 1.5.3 Global Long Acting Beta 2 Agonist Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 GSK
    • 2.1.1 GSK Details
    • 2.1.2 GSK Major Business
    • 2.1.3 GSK Long Acting Beta 2 Agonist Product and Services
    • 2.1.4 GSK Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 GSK Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca Long Acting Beta 2 Agonist Product and Services
    • 2.2.4 AstraZeneca Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 AstraZeneca Recent Developments/Updates
  • 2.3 Chiesi
    • 2.3.1 Chiesi Details
    • 2.3.2 Chiesi Major Business
    • 2.3.3 Chiesi Long Acting Beta 2 Agonist Product and Services
    • 2.3.4 Chiesi Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Chiesi Recent Developments/Updates
  • 2.4 Boehringer Ingelheim
    • 2.4.1 Boehringer Ingelheim Details
    • 2.4.2 Boehringer Ingelheim Major Business
    • 2.4.3 Boehringer Ingelheim Long Acting Beta 2 Agonist Product and Services
    • 2.4.4 Boehringer Ingelheim Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.5 Novartis
    • 2.5.1 Novartis Details
    • 2.5.2 Novartis Major Business
    • 2.5.3 Novartis Long Acting Beta 2 Agonist Product and Services
    • 2.5.4 Novartis Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Novartis Recent Developments/Updates
  • 2.6 Teva
    • 2.6.1 Teva Details
    • 2.6.2 Teva Major Business
    • 2.6.3 Teva Long Acting Beta 2 Agonist Product and Services
    • 2.6.4 Teva Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Teva Recent Developments/Updates
  • 2.7 Organon
    • 2.7.1 Organon Details
    • 2.7.2 Organon Major Business
    • 2.7.3 Organon Long Acting Beta 2 Agonist Product and Services
    • 2.7.4 Organon Long Acting Beta 2 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Organon Recent Developments/Updates

3 Competitive Environment: Long Acting Beta 2 Agonist by Manufacturer

  • 3.1 Global Long Acting Beta 2 Agonist Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Long Acting Beta 2 Agonist Revenue by Manufacturer (2018-2023)
  • 3.3 Global Long Acting Beta 2 Agonist Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Long Acting Beta 2 Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Long Acting Beta 2 Agonist Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Long Acting Beta 2 Agonist Manufacturer Market Share in 2022
  • 3.5 Long Acting Beta 2 Agonist Market: Overall Company Footprint Analysis
    • 3.5.1 Long Acting Beta 2 Agonist Market: Region Footprint
    • 3.5.2 Long Acting Beta 2 Agonist Market: Company Product Type Footprint
    • 3.5.3 Long Acting Beta 2 Agonist Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Long Acting Beta 2 Agonist Market Size by Region
    • 4.1.1 Global Long Acting Beta 2 Agonist Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Long Acting Beta 2 Agonist Consumption Value by Region (2018-2029)
    • 4.1.3 Global Long Acting Beta 2 Agonist Average Price by Region (2018-2029)
  • 4.2 North America Long Acting Beta 2 Agonist Consumption Value (2018-2029)
  • 4.3 Europe Long Acting Beta 2 Agonist Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Long Acting Beta 2 Agonist Consumption Value (2018-2029)
  • 4.5 South America Long Acting Beta 2 Agonist Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Long Acting Beta 2 Agonist Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 5.2 Global Long Acting Beta 2 Agonist Consumption Value by Type (2018-2029)
  • 5.3 Global Long Acting Beta 2 Agonist Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 6.2 Global Long Acting Beta 2 Agonist Consumption Value by Application (2018-2029)
  • 6.3 Global Long Acting Beta 2 Agonist Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 7.2 North America Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 7.3 North America Long Acting Beta 2 Agonist Market Size by Country
    • 7.3.1 North America Long Acting Beta 2 Agonist Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Long Acting Beta 2 Agonist Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 8.2 Europe Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 8.3 Europe Long Acting Beta 2 Agonist Market Size by Country
    • 8.3.1 Europe Long Acting Beta 2 Agonist Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Long Acting Beta 2 Agonist Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Long Acting Beta 2 Agonist Market Size by Region
    • 9.3.1 Asia-Pacific Long Acting Beta 2 Agonist Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Long Acting Beta 2 Agonist Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 10.2 South America Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 10.3 South America Long Acting Beta 2 Agonist Market Size by Country
    • 10.3.1 South America Long Acting Beta 2 Agonist Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Long Acting Beta 2 Agonist Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Long Acting Beta 2 Agonist Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Long Acting Beta 2 Agonist Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Long Acting Beta 2 Agonist Market Size by Country
    • 11.3.1 Middle East & Africa Long Acting Beta 2 Agonist Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Long Acting Beta 2 Agonist Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Long Acting Beta 2 Agonist Market Drivers
  • 12.2 Long Acting Beta 2 Agonist Market Restraints
  • 12.3 Long Acting Beta 2 Agonist Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Long Acting Beta 2 Agonist and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Long Acting Beta 2 Agonist
  • 13.3 Long Acting Beta 2 Agonist Production Process
  • 13.4 Long Acting Beta 2 Agonist Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Long Acting Beta 2 Agonist Typical Distributors
  • 14.3 Long Acting Beta 2 Agonist Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Long Acting Beta 2 Agonist market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists).
    This report is a detailed and comprehensive analysis for global Long Acting Beta 2 Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Long Acting Beta 2 Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Long Acting Beta 2 Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Long Acting Beta 2 Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global Long Acting Beta 2 Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Long Acting Beta 2 Agonist
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Long Acting Beta 2 Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AstraZeneca, Chiesi, Boehringer Ingelheim and Novartis, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market Segmentation
    Long Acting Beta 2 Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Serevent
    Foradil
    Other
    Market segment by Application
    COPD
    Asthma
    Other
    Major players covered
    GSK
    AstraZeneca
    Chiesi
    Boehringer Ingelheim
    Novartis
    Teva
    Organon
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Long Acting Beta 2 Agonist product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Long Acting Beta 2 Agonist, with price, sales, revenue and global market share of Long Acting Beta 2 Agonist from 2018 to 2023.
    Chapter 3, the Long Acting Beta 2 Agonist competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Long Acting Beta 2 Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Long Acting Beta 2 Agonist market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Long Acting Beta 2 Agonist.
    Chapter 14 and 15, to describe Long Acting Beta 2 Agonist sales channel, distributors, customers, research findings and conclusion.

    Buy now